AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Corvus Pharmaceuticals Presents Interim Data from Phase 1b/2 Trial of Ciforadenant for Metastatic Renal Cell Cancer at ESMO Congress 2025
ByAinvest
Saturday, Oct 18, 2025 12:36 am ET1min read
Corvus Pharmaceuticals will present interim data from a Phase 1b/2 clinical trial of ciforadenant for metastatic renal cell cancer at the European Society for Medical Oncology Congress 2025. The trial, conducted by the Kidney Cancer Research Consortium, has enrolled 50 patients with newly diagnosed or recurrent stage IV clear cell RCC. The interim data shows that the triplet therapy with ciforadenant, ipilimumab, and nivolumab is feasible and well tolerated. The presentation highlights the trial's patient demographics and clinical characteristics.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet